Citations

Showing 10 of 108152 citations.

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer
Chintakuntlawar, Ashish V. , Yin, Jun , Foote, Robert L. , Kasperbauer, Jan L. , Rivera, Michael , Asmus, Erik, Garces, Nina I., Janus, Jeffrey R. , Liu, Minetta C. , Moore, Eric J. , Neben-Wittich, M.A. , Price, Katharine A. , Ryder, Mabel , Abel, Kathryn M. Van , Hilger, Crystal, Samb, Eleyna, Bible, Keith C. , Liu, Minetta, Neben-Wittich, Michelle, Van Abel, Kathryn M , Chintakuntlawar, Ashish V , Ryder, Mabel , Daniel, J. , Morris, John C., Price, Daniel L.

Mayo Clinic

Thyroid® | October 9, 2019 | Volume: 29 | Issue: 11 | Pages: 1615-1622

10.1089/thy.2019.0086 | PMID 31595822 Get It

Background: Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival (OS) of ∼6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, having found pembrolizumab to anecdotally have limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. Methods: An investigator-initiated therapeutic phase 2 trial of pembrolizumab, 200 mg intravenously (IV) every 3 weeks, combined with chemoradiotherapy (docetaxel/doxorubicin, 20 mg/m 2 each IV weekly plus volumetric modulated arc therapy) was initiated as frontline therapy (with or without surgery) in ATC to assess efficacy and toxicities. Six-month OS was selected as the primary endpoint using a Simon's optimal design with interim analysis (targeting accrual of 25 patients; Cohort A: prior resection, Cohort B: no resection). Based on a prior patient cohort-treated similarly, but without pembrolizumab, the design was such that, if 6-month true survival is 75%, the probability of declaring the approach worthy of further pursuit would be 91%. Results: Three patients were enrolled, two with rapidly enlarging unresectable neck masses. Early tumor responses were favorable in all three, and all three satisfactorily completed: intended radiotherapy, preceding and radiotherapy-concurrent pembrolizumab, and concurrent chemoradiotherapy. However, all three patients died <6 months following therapy initiation—one from pulmonary metastases and two from otherwise unexpected fatal pulmonary complications occurring subsequent to chemoradiotherapy completion—prompting study closure. Conclusions: Although initially tolerated and effective in terms of locoregional disease control, disappointing survival outcomes compared with historical controls raise uncertainty that the piloted approach merits further pursuit in ATC.
Evaluation of a Novel Wellness Assessment Device (Preventiometer): A Feasibility Pilot Study
Nanda, S. , Mahapatra, Saswati , Lindeen, Stephanie A. , Bernau, Joleen L, Cutshall, Susanne M. , Schierwater, Bernd , Chon, Tony Y. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , Nanda, Sanjeev , Wahner-Roedler, Dietlind L

Mayo Clinic

Global Advances in Health and Medicine | October 9, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119881096 | PMID 31637111 Get It

Background Periodic wellness assessments can provide an estimate of a person’s relative risks for major diseases, but wellness visits are underused. Our suggestion is to use a comprehensive device during a single visit. Objective The goal of this pilot study was to evaluate the feasibility of a novel one-stop wellness device (Preventiometer; iPEx5 GmbH, Greifswald, Germany) for performing multiple tests and providing a comprehensive wellness assessment in a short period. Methods A Preventiometer was used to provide wellness assessments for 10 healthy volunteers who then answered a 25-question survey to rate their satisfaction with the testing and their overall impression. Results All volunteers agreed or strongly agreed with the following: The assessment reports were easy to understand, the Preventiometer met their satisfaction, the participants were comfortable during the assessment, and all measurements and testing were well coordinated. Participants liked the instant test result feature. Most (90%) agreed that the machine was useful for a quick health assessment for busy people, and 70% felt that it was time efficient. Conclusion In this feasibility pilot study, the Preventiometer performed multiple tasks and provided a comprehensive wellness assessment in a short period. Participants reported remarkably high satisfaction with the tests. A larger study is needed to prove that this is a pragmatic approach to help individuals improve their health.
Physiologic Mechanisms of Jaundice in the Newborn: A Survey of New Insights
Metge, William R., Foulk, William T., Dower, John C.

Mayo Clinic

Clinical Pediatrics | October 9, 2019 | Volume: 1 | Issue: 3 | Pages: 152-156

10.1177/000992286200100308 Get It

Comparison of drug-coated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: Systematic review and meta-analysis
Salim, Sohail Abdul , Tran, Hong , Cheungpasitporn, Wisit, Cheungpasitporn, Wisit , Abdul Salim, Sohail , Cheungpasitporn, Wisit , Thongprayoon, Charat , Fülöp, Tibor

Mayo Clinic

The Journal of Vascular Access | October 9, 2019 | Volume: 21 | Issue: 3 | Pages: 357-365

10.1177/1129729819878612 | PMID 31595799 Get It

Background: Arteriovenous fistula is the most preferred form of vascular access, but stenosis treated by balloon angioplasty is prone to restenosis. Multiple trials have been published with regard to the use of paclitaxel-coated balloon to prolong lesion patency compared to conventional balloon. Although paclitaxel-coated balloon has theoretical appeal, its use has not been widespread nationwide due to cost and lack of large-scale multicenter studies. We performed this meta-analysis to evaluate whether paclitaxel-coated balloon outperforms conventional balloon to prolong target lesion patency. Methods: PubMed/Medline, Clinical Trials.gov, EMBASE, Scopus, Web of Science, and Cochrane Central were searched from inception through April 2019 for studies that investigated the use of paclitaxel-coated balloon in arteriovenous fistula. Results: Ten studies were included in the final meta-analysis: six studies were randomized controlled trials and four studies were cohort studies. There were 911 participants with a mean age of 64.78 (±5.96) years, and 61.89% were male. Outcome of interest was target lesion primary patency, recorded at 1, 3, 6, 7, 12, and 24 months. Meta-analysis of randomized controlled trials shows that paclitaxel-coated balloons did not statistically improve target lesion primary patency compared to conventional balloons at months 1 (odds ratio = 1.54, p = 0.6373), 3 (odds ratio = 0.57, p = 0.0575), 6 (odds ratio = 0.65, p = 0.3644), 7 (odds ratio = 0.63, p = 0.0582), 12 (odds ratio = 0.64, p = 0.0612), and 24 (odds ratio = 0.43, p = 0.3452). Effect of paclitaxel-coated balloons was statistically significant for cohort studies at months 6 (odds ratio = 0.26, p = 0.0007), 12 (odds ratio = 0.21, p = 0.0001), and 24 (odds ratio = 0.23, p = 0.01). Conclusion: Paclitaxel-coated balloon showed no statistically significant improvement over conventional balloons in decreasing fistula stenosis in randomized controlled trial but were significant for cohort studies.
Clinical spectrum of individuals with pathogenic N F1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1
Koczkowska, Magdalena , Callens, Tom, Chen, Yunjia , Gomes, Alicia , Hicks, Alesha D., Sharp, Angela, Johns, Eric, Uhas, Kim, Armstrong, Linlea , Bosanko, Katherine A. , Babovic‐Vuksanovic, Dusica , Baker, Laura, Basel, Donald , Bengala, Mario, Chambers, Chelsea , Clarkson, L. Kate, Clementi, Maurizio , Cortés, Fanny, Cunningham, Mitch , D’Agostino, Daniela , Delatycki, Martin B. , Digilio, M. Cristina , Dosa, Laura, Esposito, Silvia , Freckmann, Mary‐Louise , Fauth, Christine , Giugliano, Teresa , Giustini, Sandra , Goetsch, Allison L. , Goldberg, Yael , Greenwood, Robert , Griffis, Cristin, Gripp, Karen W. , Gupta, Punita , Haan, Eric , Hachen, Rachel K., Haygarth, Tamara L., Hernández‐Chico, Concepción, Hodge, Katelyn, Hopkin, Robert J. , Hudgins, Louanne , Janssens, Sandra , Keller, Kory, Kelly‐Mancuso, Geraldine, Kochhar, Aaina , Korf, Bruce R. , Lewis, Andrea M. , Liebelt, Jan, Lichty, Angie, Listernick, Robert , Lyons, Michael J. , Maystadt, Isabelle , Ojeda, Mayra Martinez, McDougall, Carey, McGregor, Lesley , Melis, Daniela , Mendelsohn, Nancy J., Nowaczyk, Małgorzata J.M. , Ortenberg, June, Panzer, Karin, Pappas, John , Pierpont, Mary Ella , Pinna, Valentina, Pivnick, Enikö K., Pond, Dinel , Powell, Cynthia M. , Rogers, Caleb , Ruhrman‐Shahar, Noa , Rutledge, S. Lane , Saletti, Veronica , Sandaradura, Sarah A. , Schatz, Ulrich A. , Schreiber, Allison, Sellars, Elizabeth A. , Siqveland, Elizabeth, Slopis, John M. , Smith, Rosemarie, Spalice, Alberto , Stockton, David W., Streff, Haley , Theos, Amy , Tran, Grace , Trapane, Pamela , Trevisson, Eva , Ullrich, Nicole J. , Ende, Jenneke van den , Wallace, Stephanie E , Weaver, David D. , Yohay, Kaleb , Zackai, Elaine H. , Zonana, Jonathan, Zurcher, Vickie, Claes, Kathleen , Eoli, Marica , Wimmer, Katharina , Luca, Alessandro De , Messiaen, Ludwine , Trevisson, Eva , Wangler, Michael F , Claes, Kathleen B M , Wimmer, Katharina , De Luca, Alessandro , Messiaen, Ludwine M , Gupta, Punita , Bennett, James T , Fox, Stephanie, Hernández-Chico, Concepción, Piluso, Giulio , Santoro, Claudia , Scott, Daryl A , Sheffer, Ruth N. , Tomlinson, Gail Elizabeth , Vergano, Samantha A. Schrier , Martín, Yolanda , Legius, Eric

Mayo Clinic

Human Mutation | October 9, 2019 | Volume: 41 | Issue: 1 | Pages: 299-315

10.1002/humu.23929 | PMID 31595648 Get It

Micro-CT imaging of structure-to-function relationship of bone microstructure and associated vascular involvement
Ritman, Erik L., Bolander, Mark E., Fitzpatrick, Lorraine A. , Turner, Russell T.

Mayo Clinic

Technology and Health Care | October 9, 2019 | Volume: 6 | Issue: 5-6 | Pages: 403-412

10.3233/thc-1998-65-612 Get It

Micro-CT examinations of trabecular bone samples at different resolutions: 14, 7 and 2 micron level
Laval-Jeantet, A. M., Ritman, Erik L., Rüegsegger, P., Peyrin, Françoise , Salomé, M. , Cloetens, Peter

Mayo Clinic

Technology and Health Care | October 9, 2019 | Volume: 6 | Issue: 5-6 | Pages: 391-401

10.3233/thc-1998-65-611 Get It

Preoperative Optimization of the Chronic Pain Patient. Enhanced Recovery Before Surgery McAnally HB, Freeman LW, Darnall B
Wilson, Peter R, Wilson, Peter R

Mayo Clinic

Pain Medicine | October 9, 2019 | Volume: 21 | Issue: 4 | Pages: 860-861

10.1093/pm/pnz272 Get It

A Review of Viral-Related Malignancies and the Associated Imaging Findings
Consul, Nikita , Menias, Christine O. , Lubner, Meghan G. , Katabathina, Venkata S. , Chahinian, Rita, Mansour, Joseph M. , Elsayes, Khaled M. , Mansour, Joseph

Mayo Clinic

American Journal of Roentgenology | October 8, 2019 | Volume: 214 | Issue: 1 | Pages: W1-W10

10.2214/ajr.19.21357 | PMID 31593515 Get It